# Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome

> **NCT03081598** · PHASE2 · TERMINATED · sponsor: **Liminal BioSciences Ltd.** · enrollment: 104 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Metabolic Syndrome

## Interventions

- **DRUG:** PBI-4050
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03081598
- **Lead sponsor:** Liminal BioSciences Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-29
- **Primary completion:** 2018-09-06
- **Final completion:** 2018-09-06
- **Target enrollment:** 104 (ACTUAL)
- **Why stopped:** Failure to meet recruitment target during the recruitment period
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03081598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03081598, "Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03081598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*